RCKT

Several events have impacted Rocket Pharmaceuticals' stock price in the past six months. The FDA accelerated approval of KRESLADI™ led to a stock increase. The sale of a Rare Pediatric Disease Priority Review Voucher strengthened the company's balance sheet. First quarter 2026 financial results showed a net loss improvement, but the stock traded down after missing EPS estimates. A clinical hold on the RP-A501 trial for Danon disease in May 2025 caused a stock price decline, but the hold was later lifted. Overall, the stock has increased by 3.4% since the beginning of 2026.